ArticleNeurology. Clinical practice2023

No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS).

Ilya Kister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.